Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharma’s Out-licensed Drugs Spur Start-ups
by Lisa M. Jarvis
November 5, 2012
| A version of this story appeared in
Volume 90, Issue 45
Amgen and venture capital firm Kleiner Perkins Caufield & Byers have launched Atara Biotherapeutics, which will focus on developing drugs for nephrology and oncology. Amgen is kicking in six assets in various stages of development, ranging from preclinical to Phase I studies, while KPCB will provide the initial funding for the start-up. In separate news, Puma Biotechnology raised $138 million in its initial public offering. The funds will support the development of neratinib, a breast cancer drug in late-stage testing that Puma licensed last year from Pfizer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter